AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28956335
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide (NO)/cGMP pathway and NMDA receptor signaling
Trial: 28958347
Drug: GDF-15 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDF-15 therapy
Trial: 28960029
Drug: Submillisievert chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Submillisievert chest computed tomography (CT) scan (effective dose, 0.19-0.25 millisievert)
Trial: 28960096
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cells (MSCs) at doses of 0.3, 1.0, and 3.0 million cells/kg (up to 250 million cells)
Trial: 28961812
Drug: Meropenem 2000
RxNorm normalized name: meropenem 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 2000 mg/6 h by intermittent (30 min) or prolonged (3 h) infusion for A. baumannii
Trial: 28961812
Drug: Meropenem 6000
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 6000 mg/day by continuous infusion for A. baumannii
Trial: 28961812
Drug: Meropenem 2000
RxNorm normalized name: meropenem 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 2000 mg/8 h or 1000 mg/6 h for P. aeruginosa
Trial: 28961812
Drug: Meropenem 1000
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1000 mg/8 h for patients with CLCR ≤ 100 mL/min
Trial: 28962047
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg Dexamethasone Suppression Test (DST)
Trial: 28962047
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg Dexamethasone Suppression Test (DST)
Trial: 28963781
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy (356 patients total)
Trial: 28964314
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg rocuronium
Trial: 28964826
Drug: Mixed model
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed model (HL) 2d/week consisting of H training 1d/week and L training 1d/week
Trial: 28965093
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment for hypertension (antihypertensive medication)
Trial: 28965093
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment for dyslipidaemia (statin)
Trial: 28965093
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment for diabetes (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker)
Trial: 28965093
Drug: Treatment gap
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment gap in dyslipidaemia
Trial: 28965185
Drug: Erdafitinib 2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdafitinib 2, 4, or 6 mg daily dosing schedule
Trial: 28965185
Drug: Erdafitinib 10
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erdafitinib 10 mg or 12 mg intermittent dosing schedule
Trial: 28965185
Drug: Erdafitinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdafitinib (all doses)
Trial: 28967387
Drug: Bacteriologic criterion
RxNorm normalized name: Bacteriolysin sal-1 (staphylococcus phage sap-1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteriologic criterion of ≥10,000 colony forming units/mL of a single organism
Trial: 28968874
Drug: Non-adjuvanted influenza
RxNorm normalized name: Influenza, adjuvanted, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted influenza A/California/7/2009 (pH1N1) vaccine
Trial: 28970161
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with colistin (9 million UI/day) and tigecycline (100 mg/day)
Trial: 28970161
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with colistin (9 million UI/day)
Trial: 28970161
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with colistin and tigecycline
Trial: 28970161
Drug: Empirical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical therapy with colistin
Trial: 28970161
Drug: Renal dysfunction
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal dysfunction before treatment
Trial: 28970332
Drug: Visual assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual assessments of fundic accommodation by trained readers (nuclear medicine and radiology physicians) during solid-meal gastric emptying scintigraphy (GES)
Trial: 28971861
Drug: Micafungin; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin; specific dosage and duration not mentioned.
Trial: 28971900
Drug: Buparlisib 100
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib 100 mg once daily until progression, intolerance, or withdrawal of consent
Trial: 28971900
Drug: Buparlisib 100
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib 100 mg once daily
Trial: 28972011
Drug: Oral leniolisib
RxNorm normalized name: Leniolisib
DrugBank: Leniolisib (DB16217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral leniolisib (CDZ173)
Trial: 28973026
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum phosphate in patients with serum albumin lower than 3.9 g/dL
Trial: 28973164
Drug: Isoglycemic Intravenous
RxNorm normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoglycemic Intravenous Glucose Infusion (IIGI)
Trial: 28973403
Drug: Rilotumumab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab monotherapy (10 or 20 mg/kg IV every 2 weeks)
Trial: 28973403
Drug: Rilotumumab in
RxNorm normalized name: Rilotumumab
DrugBank: Rilotumumab (DB11972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab in combination with cisplatin (80 mg/m2 on Day 1) and capecitabine (1000 mg/m2 twice daily on Days 1-14 of every 21-day cycle)
Trial: 28973403
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events related to any treatment
Trial: 28973403
Drug: Dose-limiting toxicities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-limiting toxicities (DLTs)
Trial: 28973520
Drug: TAVR vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAVR vs medical treatment, n=165
Trial: 28973622
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d of biotin supplementation for 7 days
Trial: 28974059
Drug: Augmented pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented pulse pressure variation (PPV12) induced by 2-min ventilation with a tidal volume (V T ) of 12 ml kg -1
Trial: 28974059
Drug: Standard pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pulse pressure variation (PPV8) with a tidal volume of 8 ml kg -1
Trial: 28975039
Drug: Creative music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creative music therapy (CMT), approximately 20 minutes duration, three times per week, delivered by a trained music therapist singing in lullaby style, adjusted to the infant's rhythm and affect.
Trial: 28976556
Drug: SAR260301 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR260301 (100 mg to 440 mg once daily)
Trial: 28976817
Drug: Lenti-D gene
RxNorm normalized name: Lenti-d
DrugBank: Elivaldogene tavalentivec (DB19095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenti-D gene therapy (autologous CD34+ cells transduced with elivaldogene tavalentivec)
Trial: 28976817
Drug: Lenti-D gene
RxNorm normalized name: Lenti-d
DrugBank: Elivaldogene tavalentivec (DB19095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenti-D gene therapy
Trial: 28977361
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (unoperated)
Trial: 28977630
Drug: Antinuclear antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antinuclear antibodies (ACA)
Trial: 28978797
Drug: Aprepitant 375
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 375 mg per day for 28 days
Trial: 28978801
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (5,000 IU cholecalciferol daily for 90 days)
Trial: 28979661
Drug: Ingenol Mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol Mebutate Gel 0.015%
Trial: 28980004
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin 1.8 mg/kg infused over 30 minutes every 21 days
Trial: 28980446
Drug: BIVV009 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIVV009 (60 mg/kg, 4 weekly doses)
Trial: 28982495
Drug: High-energy breakfast
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy breakfast (contributing to >20% of total daily energy intake)
Trial: 28982495
Drug: Skipping breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skipping breakfast (consuming <5% of total daily energy)
Trial: 28982495
Drug: Low-energy breakfast
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy breakfast (contributing between 5% and 20% of total daily energy intake)
Trial: 28982667
Drug: Excretion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excretion of endogenous cholesterol
Trial: 28982814
Drug: Emotion regulation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion regulation group therapy (ERGT)
Trial: 28983018
Drug: Moxetumomab pasudotox
RxNorm normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Moxetumomab pasudotox (30 µg/kg every other day for 6 doses)
Trial: 28983018
Drug: Moxetumomab pasudotox
RxNorm normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Moxetumomab pasudotox (50 µg/kg for 10 doses)
Trial: 28983018
Drug: Moxetumomab pasudotox
RxNorm normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Moxetumomab pasudotox (40 µg/kg for 10 doses)
Trial: 28983018
Drug: Moxetumomab pasudotox
RxNorm normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Moxetumomab pasudotox (50 µg/kg × 6 doses)
Trial: 28984517
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) - either intensity modulated (IMRT) or 3D conformal (3DCRT), 54 Gy in 30 fractions
Trial: 28985241
Drug: High-Salt (HS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Salt (HS) diet (18.0 g/day NaCl)
Trial: 28985241
Drug: Low-Salt (LS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Salt (LS) diet (3.0 g/day NaCl)
Trial: 28985241
Drug: High-Salt +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Salt + K+ (HS + K+) diet (18.0 g/day NaCl and 4.5 g/day KCl)
Trial: 28986407
Drug: USPIO-enhanced MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USPIO-enhanced MRI (ferumoxytol, 4 mg/kg)
Trial: 28986931
Drug: Standardised anaesthesia,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised anaesthesia, intravenous coloading, and prophylactic vasopressor treatment
Trial: 28988934
Drug: WTX101 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WTX101 monotherapy at a starting dose of 15-60 mg/day for the first 4-8 weeks, with response-guided individualised dosing for the remaining weeks up to week 24.
Trial: 28988934
Drug: WTX101 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WTX101 monotherapy
Trial: 28989706
Drug: Standard Dialectical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Dialectical Behaviour Therapy (DBT) for 12 months
Trial: 28991061
Drug: 0.5% Ropivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Ropivacaine, initial volume 30 mL, adjusted by 2 mL based on previous subject's response
Trial: 28991112
Drug: Dexmedetomidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine administered over 15 minutes, dosage determined by the Dixon up-and-down method.
Trial: 28994660
Drug: Rilpivirine (RPV)
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (RPV) 25 mg, once daily
Trial: 29016235
Drug: Telemedicine support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine support group intervention using encrypted tablet-based videoconferencing.
Trial: 29660005
Drug: Cabozantinib 140
RxNorm normalized name: cabozantinib 140 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 140 mg/day
Trial: 29017455
Drug: Remifentanil adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil adjusted to approximately 6.5 ng/mL before head fixation
Trial: 29017845
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of daily toothbrushing
Trial: 29017994
Drug: BPTrack, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPTrack, a clinical pharmacist-led mHealth intervention for hypertension management, involving home blood pressure monitoring and medication adherence over a 12-week period.
Trial: 29018537
Drug: AMG 811
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 811 (6, 20 or 60 mg)
Trial: 29018537
Drug: AMG 811
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 811 (20, 60 or 120 mg)
Trial: 29021813
Drug: Phytosterols 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterols 800 mg
Trial: 29021813
Drug: Red yeast
RxNorm normalized name: red yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red yeast rice standardized to contain 5 mg monacolins
Trial: 29021813
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of phytosterols and red yeast rice
Trial: 29025008
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg qd
Trial: 29025008
Drug: Carvedilol 12.5
RxNorm normalized name: carvedilol 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5 mg bid
Trial: 29025008
Drug: Carvedilol with
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol with inhaled LAMA (tiotropium) and LABA (formoterol)
Trial: 29026685
Drug: Carfilzomib infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib infusion (27 and 56 mg/m2)
Trial: 29027607
Drug: Patient-reported outcome
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-reported outcome measure (PRO) for barriers to antiretroviral therapy (ART) adherence
Trial: 29028966
Drug: Any recent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any recent drug use
Trial: 29029122
Drug: HZ/su (adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZ/su (adjuvanted herpes zoster subunit vaccine), 2 doses 2 months apart
Trial: 29029122
Drug: HZ/su (adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZ/su (adjuvanted herpes zoster subunit vaccine)
Trial: 29029127
Drug: GBS vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS vaccine (0.5, 2.5, or 5.0 μg of each of 3 CRM197-glycoconjugates)
Trial: 29029127
Drug: GBS vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS vaccine
Trial: 29030503
Drug: Blended therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended therapy combining face-to-face problem solving and a smartphone app
Trial: 29031861
Drug: Treatment team-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment team-directed nutrition (TTDN)
Trial: 29033369
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of C. symbiosum and FIT
Trial: 29033369
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all markers (C. symbiosum, F. nucleatum, FIT, CEA)
Trial: 29033896
Drug: KDT501 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KDT501 treatment for 28 days
Trial: 29034366
Drug: Sorafenib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib combined with chemotherapy
Trial: 29035939
Drug: 40-mg olmesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-mg olmesartan
Trial: 29036345
Drug: Cabozantinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (100 mg/day)
Trial: 29037983
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan at 5.4 mg/kg or greater
Trial: 29038072
Drug: Levonorgestrel 52
RxNorm normalized name: LEVONORGESTREL 52MG INSERT INTRAUTERINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 52 mg IUS
Trial: 29038184
Drug: Participatory action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participatory action research (PAR) approach to improve antibiotic prescribing quality
Trial: 29038184
Drug: Process evaluation
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Process evaluation and theory building on improving antibiotic prescribing
Trial: 29038338
Drug: CD19-targeted chimeric
RxNorm normalized name: Autologous anti-CD20/CD19-targeting tandem CAR T cells MB-CART2019.1
DrugBank: Zamtocabtagene autoleucel (DB18764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-targeted chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy
Trial: 29038891
Drug: Cyanocobalamin 1.5
RxNorm normalized name: cyanocobalamin 1.5 MG Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanocobalamin 1.5 µg
Trial: 29038891
Drug: Cyanocobalamin 3
RxNorm normalized name: CYANOCOBALAMIN 30MCG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanocobalamin 3 µg
Trial: 29038891
Drug: Cyanocobalamin 6
RxNorm normalized name: cyanocobalamin 6 MG Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanocobalamin 6 µg
Trial: 29038891
Drug: Cyanocobalamin 9
RxNorm normalized name: VITAMIN A ACETATE 2500 [iU] / ASCORBIC ACID 100 mg / CHOLECALCIFEROL 600 [iU] / .ALPHA.-TOCOPHEROL, DL- 30 [iU] / THIAMINE HYDROCHLORIDE 1.5 mg / RIBOFLAVIN 1 mg / NIACINAMIDE 20 mg / PYRIDOXINE HYDROCHLORIDE 2 mg / LEVOMEFOLATE GLUCOSAMINE 216 ug / CYANOCOBALAMIN 9 ug / BIOTIN 45 ug / CALCIUM PANTOTHENATE 10 mg / IRON PENTACARBONYL 9 mg / ZINC OXIDE 12 mg / COPPER 1 mg / SODIUM FLUORIDE 0.25 mg ORAL TABLET, CHEWABLE [Quflora FE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanocobalamin 9 µg (normal status)
Trial: 29038891
Drug: Cyanocobalamin (6
RxNorm normalized name: Cyanocobalamin (60Co)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanocobalamin (6 µg) vs 3 µg (low status)
Trial: 29038891
Drug: Cyanocobalamin (6
RxNorm normalized name: Cyanocobalamin (60Co)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanocobalamin (6 µg) vs 9 µg (normal status)
Trial: 29040433
Drug: Epinephrine administration
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine administration